Observations placeholder

ProcalAmine Description

ProcalAmine® (3% Amino Acid and 3% Glycerin Injection with Electrolytes) is a sterile, nonpyrogenic, moderately hypertonic intravenous injection containing crystalline amino acids, a nonprotein energy substrate and maintenance electrolytes. A 1000 mL unit provides a total of 29 g of protein equivalent (4.6 g N) and 130 nonprotein calories.

All amino acids designated USP are the "L"-isomer with the exception of Glycine USP which does not have an isomer.

Each 100 mL contains:
Nonprotein energy source:
Glycerin USP (glycerol) ..............................................................................  3.0 g

Essential amino acids
Isoleucine USP ..........................................................................................  0.21 g
Leucine USP .............................................................................................  0.27 g
Lysine .......................................................................................................  0.22 g
  (added as Lysine Acetate USP ................................................................  0.31 g)
Methionine USP ........................................................................................  0.16 g
Phenylalanine USP ....................................................................................  0.17 g
Threonine USP ..........................................................................................  0.12 g
Tryptophan USP ......................................................................................  0.046 g
Valine USP ................................................................................................  0.20 g

Nonessential amino acids

Alanine USP ..............................................................................................  0.21 g
Glycine USP ..............................................................................................  0.42 g
Arginine USP .............................................................................................  0.29 g
Histidine USP............................................................................................  0.085 g
Proline USP ...............................................................................................  0.34 g
Serine USP ................................................................................................  0.18 g
Cysteine ...................................................................................................<0.014 g
  (as Cysteine HCl•H2O USP ...................................................................<0.020 g)
Sodium Acetate•3H2O USP........................................................................  0.20 g
Magnesium Acetate•4H2O.........................................................................  0.054 g
Calcium Acetate•H2O ...............................................................................  0.026 g
Sodium Chloride USP .................................................................................  0.12 g
Potassium Chloride USP..............................................................................  0.15 g
Phosphoric Acid NF .................................................................................  0.041 g
Potassium Metabisulfite NF (as an antioxidant) ............................................<0.05 g
Water for Injection USP ....................................................................................  qs

pH adjusted with Glacial Acetic Acid USP
pH: 6.8 (6.5–7.0), Calculated Osmolarity: 735 mOsmol/liter
Concentration of Electrolytes (mEq/liter): Sodium 35; Potassium 24.5; Calcium 3
Magnesium 5; Chloride 41; Phosphate (HPO ) 71; Acetate 472

1  3.5 mmole/liter; 10.9 mg% P

2  Acetate is provided as inorganic acetate salts (23 mEq/liter), acetic acid (9 mEq/liter), and lysine acetate (15 mEq/liter). It is thought that acetate from lysine acetate and acetic acid, under the conditions of parenteral nutrition does not impact net acid/base balance when renal and respiratory functions are normal. Clinical experience seems to support this thinking, although confirmatory experimental evidence is not available.

On Jan, 29, 2016: 39 people reported to have side effects when taking Procalamine. Among them, 2 people (5.13%) have Hallucination.